PH12021550218A1 - Use of riluzole oral disintigrating tablets for treating diseases - Google Patents

Use of riluzole oral disintigrating tablets for treating diseases

Info

Publication number
PH12021550218A1
PH12021550218A1 PH12021550218A PH12021550218A PH12021550218A1 PH 12021550218 A1 PH12021550218 A1 PH 12021550218A1 PH 12021550218 A PH12021550218 A PH 12021550218A PH 12021550218 A PH12021550218 A PH 12021550218A PH 12021550218 A1 PH12021550218 A1 PH 12021550218A1
Authority
PH
Philippines
Prior art keywords
riluzole
oral
disintigrating
tablets
treating diseases
Prior art date
Application number
PH12021550218A
Other languages
English (en)
Inventor
Vladimir Coric
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of PH12021550218A1 publication Critical patent/PH12021550218A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH12021550218A 2018-08-16 2021-01-28 Use of riluzole oral disintigrating tablets for treating diseases PH12021550218A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862764864P 2018-08-16 2018-08-16
PCT/US2019/046709 WO2020037152A1 (en) 2018-08-16 2019-08-15 Use of riluzole oral disintigrating tablets for treating diseases

Publications (1)

Publication Number Publication Date
PH12021550218A1 true PH12021550218A1 (en) 2021-12-06

Family

ID=69525906

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550218A PH12021550218A1 (en) 2018-08-16 2021-01-28 Use of riluzole oral disintigrating tablets for treating diseases

Country Status (14)

Country Link
US (1) US20210315865A1 (cg-RX-API-DMAC7.html)
EP (1) EP3836922B1 (cg-RX-API-DMAC7.html)
JP (2) JP2021534160A (cg-RX-API-DMAC7.html)
KR (1) KR20210045423A (cg-RX-API-DMAC7.html)
CN (1) CN112584831A (cg-RX-API-DMAC7.html)
AU (1) AU2019322889A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021002692A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190544A1 (cg-RX-API-DMAC7.html)
ES (1) ES2987802T3 (cg-RX-API-DMAC7.html)
IL (1) IL280657A (cg-RX-API-DMAC7.html)
MX (2) MX2021001563A (cg-RX-API-DMAC7.html)
PH (1) PH12021550218A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100880VA (cg-RX-API-DMAC7.html)
WO (1) WO2020037152A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299301A (en) * 2020-06-24 2023-02-01 Biohaven Therapeutics Ltd Compositions and methods for the treatment of obsessive compulsive disorder
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
LT4243797T (lt) 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114177153B (zh) * 2021-12-20 2023-04-07 平顶山市第二人民医院 一种利鲁唑口崩片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2004047793A1 (en) * 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
US9241902B2 (en) * 2003-12-17 2016-01-26 R.P. Scherer Technologies, Llc Chewable soft capsules containing ungelatinized starch
ES2819303T3 (es) * 2005-04-05 2021-04-15 Univ Yale Agentes moduladores del glutamato en el tratamiento de trastornos mentales
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
US9434704B2 (en) * 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
RS59490B1 (sr) * 2014-11-21 2019-12-31 Biohaven Therapeutics Ltd Sublingvalna formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US10258611B2 (en) * 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
DK3265448T3 (da) * 2015-03-03 2022-03-28 Biohaven Therapeutics Ltd Riluzol-prodrugs og anvendelse deraf
MX2019009038A (es) * 2017-01-31 2019-12-09 L Manfredi Paolo D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso.

Also Published As

Publication number Publication date
MX2024007642A (es) 2024-07-04
EP3836922A4 (en) 2022-05-04
JP2024010017A (ja) 2024-01-23
SG11202100880VA (en) 2021-02-25
WO2020037152A1 (en) 2020-02-20
AU2019322889A1 (en) 2021-03-04
EP3836922B1 (en) 2024-08-07
IL280657A (en) 2021-03-25
US20210315865A1 (en) 2021-10-14
EP3836922A1 (en) 2021-06-23
MX2021001563A (es) 2021-06-15
EA202190544A1 (ru) 2021-06-18
EP3836922C0 (en) 2024-08-07
CA3109769A1 (en) 2020-02-20
JP2021534160A (ja) 2021-12-09
ES2987802T3 (es) 2024-11-18
BR112021002692A2 (pt) 2021-05-11
CN112584831A (zh) 2021-03-30
KR20210045423A (ko) 2021-04-26

Similar Documents

Publication Publication Date Title
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2020012180A (es) Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina.
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
PH12019500025A1 (en) Cancer treatment combinations
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2015038135A5 (cg-RX-API-DMAC7.html)
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
PH12021553056A1 (en) Modified release formulations and uses thereof
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
EP4640220A3 (en) Orally disintegrating pharmaceutical compositions of apixaban
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
JP2016505050A5 (cg-RX-API-DMAC7.html)
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
IL250852B (en) Periodontal preparation
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JOP20230099A1 (ar) تركيبات صيدلية
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний